Mels Assykbayev
Mels Assykbayev has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Saitkarim Abdugafarov
LLP "National Research Oncology Center", Department of Hepatopancreatobiliary surgery, Oncohepatology and Organ transplantation, Astana, Republic of Kazakhstan
5 shared publications - Aida Zhenissova
“University Medical Center” Corporate Fund, Astana, Kazakhstan
2 shared publications - Aidos Bolatov
Shenzhen University Medical School, Shenzhen University, Shenzhen, China
2 shared publications - Aizhan Abdikadirova
Clinical Academic Department of Laboratory Medicine, Pathology, and Genetics “University Medical Center” Corporate Fund Astana Kazakhstan
2 shared publications - Almira Manatova
National Research Oncology Center, Astana, Republic of Kazakhstan
2 shared publications - Dias Malik
“University Medical Center” Corporate Fund, Astana, Kazakhstan
2 shared publications
Latest Publications
- Open Access
- 5 November 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-18
Whole-exome sequencing of kidney transplant recipients and donors: insights into end-stage renal disease and post-transplant genetic risk
Kidney transplantation is the preferred treatment for end-stage renal disease (ESRD), yet challenges persist in long-term graft survival and post-transplant complications. Genomic profiling, especially whole-exome sequencing (WES), offers new opportunities to personalize donor-recipient matching and predict transplant outcomes. This study aimed to explore the genetic landscape of both transplant recipients and donors using WES. This prospective cohort study included 64 kidney transplant recipients (51 adults, 13 pediatric) and 61 donors in Kazakhstan. WES was performed to identify monogenic causes of ESRD, evaluate rejection-associated immune polymorphisms (31 SNPs), and screen for post-transplant risk using a 355-gene Transplant Morbidity Panel. Variants were classified following ACMG/AMP guidelines, and allele frequencies were compared to global reference datasets. Among recipients, pathogenic/likely pathogenic variants were found in 15.4% of pediatric and 9.1% of adult cases, with additional variants of uncertain significance detected in 23.1% and 23.6%, respectively. WES identified monogenic nephropathies including Alport syndrome, cystinuria, and polycystic kidney disease. In donors, 13.1% carried variants associated with latent renal or systemic conditions despite no clinical manifestation at donation. The APOE p.Cys130Arg variant, linked to lipid dysregulation, was observed more frequently in recipients (allele frequency 0.17) than donors (0.09), though not statistically significant. Among the 31 SNPs evaluated, significant associations with acute rejection were observed for IL1B rs1143634 and TP53 rs1625895 under dominant models. IL1B carriers showed increased rejection risk (OR = 4.62, p = 0.039), whereas TP53 carriers appeared protected (OR = 0.058, p = 0.027). Given the limited number of rejection cases, these findings should be considered exploratory and require validation in larger cohorts. Additionally, 44.3% of recipients carried at least one pathogenic or likely pathogenic variant in the Transplant Morbidity Panel, particularly in genes related to malignancy, cardiomyopathy, and monogenic diabetes. This study provides one of the first applications of WES in a Central Asian kidney transplant population. Findings highlight the prevalence of monogenic and comorbid risk variants in both recipients and donors and support the use of genomic screening for improving pre- and post-transplant care. The identification of immune-related SNPs and extra-renal findings further underscores the utility of WES for personalized transplant management. Integration of genomics into transplant workflows may help address the ongoing gap between clinical need and transplant outcomes, particularly in low-resource settings.
- 5 November 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-18
Open AccessWhole-exome sequencing of kidney transplant recipients and donors: insights into end-stage renal disease and post-transplant genetic risk
Kidney transplantation is the preferred treatment for end-stage renal disease (ESRD), yet challenges persist in long-term graft survival and post-transplant complications. Genomic profiling, especially whole-exome sequencing (WES), offers new opportunities to personalize donor-recipient matching and predict transplant outcomes. This study aimed to explore the genetic landscape of both transplant recipients and donors using WES. This prospective cohort study included 64 kidney transplant recipients (51 adults, 13 pediatric) and 61 donors in Kazakhstan. WES was performed to identify monogenic causes of ESRD, evaluate rejection-associated immune polymorphisms (31 SNPs), and screen for post-transplant risk using a 355-gene Transplant Morbidity Panel. Variants were classified following ACMG/AMP guidelines, and allele frequencies were compared to global reference datasets. Among recipients, pathogenic/likely pathogenic variants were found in 15.4% of pediatric and 9.1% of adult cases, with additional variants of uncertain significance detected in 23.1% and 23.6%, respectively. WES identified monogenic nephropathies including Alport syndrome, cystinuria, and polycystic kidney disease. In donors, 13.1% carried variants associated with latent renal or systemic conditions despite no clinical manifestation at donation. The APOE p.Cys130Arg variant, linked to lipid dysregulation, was observed more frequently in recipients (allele frequency 0.17) than donors (0.09), though not statistically significant. Among the 31 SNPs evaluated, significant associations with acute rejection were observed for IL1B rs1143634 and TP53 rs1625895 under dominant models. IL1B carriers showed increased rejection risk (OR = 4.62, p = 0.039), whereas TP53 carriers appeared protected (OR = 0.058, p = 0.027). Given the limited number of rejection cases, these findings should be considered exploratory and require validation in larger cohorts. Additionally, 44.3% of recipients carried at least one pathogenic or likely pathogenic variant in the Transplant Morbidity Panel, particularly in genes related to malignancy, cardiomyopathy, and monogenic diabetes. This study provides one of the first applications of WES in a Central Asian kidney transplant population. Findings highlight the prevalence of monogenic and comorbid risk variants in both recipients and donors and support the use of genomic screening for improving pre- and post-transplant care. The identification of immune-related SNPs and extra-renal findings further underscores the utility of WES for personalized transplant management. Integration of genomics into transplant workflows may help address the ongoing gap between clinical need and transplant outcomes, particularly in low-resource settings.
- Open Access
- 30 December 2024
- Published by Semey Medical University in Наука и здравоохранение
- No. 6(26),p. 142-151
DIAGNOSIS AND TREATMENT OF KIDNEY TRANSPLANT REJECTION: A LITERATURE REVIEW.
Introduction. Kidney transplantation is the only radical method of treating most terminal stages of chronic renal failure. Acute rejection of the transplanted kidney is one of the main and frequently encountered complications in recipients, occurring a few days or months after the transplantation, whether from a living or deceased donor, as a manifestation of the body's immune response to foreign tissue. The aim is to review and analyze the current literature on the diagnosis and treatment of kidney transplant rejection, with a focus on acute and hyperacute rejection Search strategy: Using Pubmed, Google scholar search engine, all articles that included keywords “kidney transplantation” and “rejection”, “donor-specific antibodies” were retrieved. In total 50 search results emerged for the 2014-2024 timeline, the last 10 years. Results. Acute rejection of the transplanted kidney results from the immune system recognizing the transplanted organ as foreign and mounting an immune response that leads to the rejection and destruction of the organ's cells. As for hyperacute rejection, it is caused by pre-formed antibodies that trigger a rejection reaction within the first 72 hours after organ transplantation. The manifestations and course of the disease are quite diverse, as are the consequences of developing this complication, so early diagnosis and treatment are crucial. Conclusion. Despite the existing risk prediction algorithms, these complications occur with alarming regularity, including in our country. Combined with imperfect outpatient management practices for recipients and the absence of protocol biopsies, these factors directly impact survival rates. Введение. Трансплантация почки является единственным радикальным методом лечения большинства терминальных стадий хронической почечной недостаточности. Острая реакция отторжения трансплантированной почки является одной из основных и часто встречающихся осложнений у реципиентов, возникающих через несколько дней или месяцев после трансплантации, будь то от живого или умершего донора, как проявление иммунного ответа организма на чуждую ткань. Цель. Обзор и анализ современной литературы по диагностике и лечению отторжения трансплантированной почки, с акцентом на острую и сверхострую реакцию отторжения. Стратегия поиска. С использованием PubMed и Google Scholar были найдены все статьи, содержащие ключевые слова «трансплантация почки» и «отторжение», «специфические антитела к донору». В результате поиска за период с 2014 по 2024 годы было получено 50 статьи. Результаты. Острая реакция отторжения трансплантированной почки возникает из-за того, что иммунная система распознает трансплантированный орган как чуждый и инициирует иммунный ответ, который приводит к отторжению и разрушению клеток органа. Сверхострое отторжение вызывается предобразованными антителами, которые запускают реакцию отторжения в течение первых 72 часов после трансплантации органа. Проявления и течение заболевания довольно разнообразны, как и последствия развития этого осложнения, поэтому ранняя диагностика и лечение имеют решающее значение. Заключение. Несмотря на существующие алгоритмы прогнозирования рисков, эти осложнения возникают с тревожной регулярностью, включая нашу страну. В сочетании с несовершенными практиками амбулаторного наблюдения за реципиентами и отсутствием протокольных биопсий эти факторы напрямую влияют на показатели выживаемости. Кіріспе. Бүйректі трансплантациялау созылмалы бүйрек жеткіліксіздігінің терминалды сатыларын емдеудің жалғыз радикалды әдісі болып табылады. Трансплантацияланған бүйректің жедел қабылдамау реакциясы реципиенттерде жиі кездесетін негізгі асқынулардың бірі болып саналады, ол тірі немесе қайтыс болған донордан кейін трансплантациядан бірнеше күн немесе айлар өткеннен кейін пайда болады және ағзаның бөгде тінге иммундық жауабы ретінде көрінеді. Мақсаты. Жедел және өте жедел бас тарту қабылдамау реакциясына баса назар аудара отырып, трансплантацияланған бүйректі қабылдамауды...
- 30 December 2024
- Published by Semey Medical University in Наука и здравоохранение
- No. 6(26),p. 142-151
Open AccessDIAGNOSIS AND TREATMENT OF KIDNEY TRANSPLANT REJECTION: A LITERATURE REVIEW.
Introduction. Kidney transplantation is the only radical method of treating most terminal stages of chronic renal failure. Acute rejection of the transplanted kidney is one of the main and frequently encountered complications in recipients, occurring a few days or months after the transplantation, whether from a living or deceased donor, as a manifestation of the body's immune response to foreign tissue. The aim is to review and analyze the current literature on the diagnosis and treatment of kidney transplant rejection, with a focus on acute and hyperacute rejection Search strategy: Using Pubmed, Google scholar search engine, all articles that included keywords “kidney transplantation” and “rejection”, “donor-specific antibodies” were retrieved. In total 50 search results emerged for the 2014-2024 timeline, the last 10 years. Results. Acute rejection of the transplanted kidney results from the immune system recognizing the transplanted organ as foreign and mounting an immune response that leads to the rejection and destruction of the organ's cells. As for hyperacute rejection, it is caused by pre-formed antibodies that trigger a rejection reaction within the first 72 hours after organ transplantation. The manifestations and course of the disease are quite diverse, as are the consequences of developing this complication, so early diagnosis and treatment are crucial. Conclusion. Despite the existing risk prediction algorithms, these complications occur with alarming regularity, including in our country. Combined with imperfect outpatient management practices for recipients and the absence of protocol biopsies, these factors directly impact survival rates. Введение. Трансплантация почки является единственным радикальным методом лечения большинства терминальных стадий хронической почечной недостаточности. Острая реакция отторжения трансплантированной почки является одной из основных и часто встречающихся осложнений у реципиентов, возникающих через несколько дней или месяцев после трансплантации, будь то от живого или умершего донора, как проявление иммунного ответа организма на чуждую ткань. Цель. Обзор и анализ современной литературы по диагностике и лечению отторжения трансплантированной почки, с акцентом на острую и сверхострую реакцию отторжения. Стратегия поиска. С использованием PubMed и Google Scholar были найдены все статьи, содержащие ключевые слова «трансплантация почки» и «отторжение», «специфические антитела к донору». В результате поиска за период с 2014 по 2024 годы было получено 50 статьи. Результаты. Острая реакция отторжения трансплантированной почки возникает из-за того, что иммунная система распознает трансплантированный орган как чуждый и инициирует иммунный ответ, который приводит к отторжению и разрушению клеток органа. Сверхострое отторжение вызывается предобразованными антителами, которые запускают реакцию отторжения в течение первых 72 часов после трансплантации органа. Проявления и течение заболевания довольно разнообразны, как и последствия развития этого осложнения, поэтому ранняя диагностика и лечение имеют решающее значение. Заключение. Несмотря на существующие алгоритмы прогнозирования рисков, эти осложнения возникают с тревожной регулярностью, включая нашу страну. В сочетании с несовершенными практиками амбулаторного наблюдения за реципиентами и отсутствием протокольных биопсий эти факторы напрямую влияют на показатели выживаемости. Кіріспе. Бүйректі трансплантациялау созылмалы бүйрек жеткіліксіздігінің терминалды сатыларын емдеудің жалғыз радикалды әдісі болып табылады. Трансплантацияланған бүйректің жедел қабылдамау реакциясы реципиенттерде жиі кездесетін негізгі асқынулардың бірі болып саналады, ол тірі немесе қайтыс болған донордан кейін трансплантациядан бірнеше күн немесе айлар өткеннен кейін пайда болады және ағзаның бөгде тінге иммундық жауабы ретінде көрінеді. Мақсаты. Жедел және өте жедел бас тарту қабылдамау реакциясына баса назар аудара отырып, трансплантацияланған бүйректі қабылдамауды...
- Open Access
- 14 November 2024
- Published by Semey Medical University in Наука и здравоохранение
- No. 4(26),p. 261-266
PRIMARY RECURRENT FOCAL SEGMENTAL GLOMERULOSCLEROSIS AFTER KIDNEY TRANSPLANTATION. CASE STUDY.
Primary recurrent focal segmental glomerulosclerosis (FSGS) after kidney transplantation (KT) is a serious complication and a significant risk factor for graft loss. The incidence of FSGS worldwide varies from 1.4 to 21 cases per million population. FSGS develops due to damage to the visceral epithelial cells of the kidney glomerulus (podocytes) and is classified as a "podocytopathy." Objective. This study aims to demonstrate an early recurrence of FSGS with the development of nephrotic syndrome based on a clinical case and to evaluate the short-term feasibility of plasmapheresis sessions. Methods. The article describes a clinical case of early recurrence of FSGS with the development of nephrotic syndrome. The primary treatment for disease recurrence after kidney transplantation includes plasmapheresis sessions and the administration of rituximab. Results. Analysis of the clinical case revealed that kidney graft thrombosis was a consequence of a drop in blood pressure and a slowdown in blood flow at the anastomosis site during a plasmapheresis session, ultimately leading to graft loss and the patient's return to dialysis therapy. Conclusions. For subsequent planned kidney transplantation, the patient is at extremely high risk of disease recurrence according to the literature, making the procedure not feasible in the short term. Первичный рецидивирующий фокально-сегментарный гломерулосклероз (ФСГС) после трансплантации почки (ТП) является серьезным осложнением и значимым фактором риска потери трансплантированной почки. По разным оценкам в мире заболеваемость ФСГС варьируется от 1,4 до 21 случая на миллион населения. ФСГС развивается вследствие повреждения висцеральных эпителиальных клеток клубочка почек (подоцитов) и относится к группе «подоцитопатий». Целью данного исследования. На примере описанного клинического случая указать на необходимость оценки рисков возврата заболевания ФСГС после трансплантации почки, ввиду быстрого возврата заболевания с развитием нефротического синдрома с потерей функции пересаженного органа. В статье описывается клинический случай проведения трансплантации почки от живого родственного донора, у пациента с хронической болезнью почек 5 стадии в исходе ФСГС, с ранним возвратом заболевания De novo, с развитием нефротического синдрома. Основным лечением в рецидиве заболевания после трансплантации почки является проведение сеансов плазмофереза и введение ритуксимаба. Результаты исследования. В результате анализа клинического случая было выявлено, что тромбоз трансплантата почки явился следствием падения артериального давления и замедления скорости кровотока в зоне анастомоза на фоне проведенного сеанса плазмафереза, что в конечном итоге привело к потере графта и возврата пациента на заместительную почечную терапию. Выводы. Для последующей предполагаемой трансплантации почки по литературным данным пациент имеет крайне высокие риски возврата заболевания, что делает проведение данной процедуры в краткосрочной перспективе не целесообразным. Бүйрек трансплантациясынан кейінгі бастапқы қайталанатын фокальді-сегменттік гломерулосклероз (ФСГС) ауыр асқыну және трансплантацияланған бүйректің жоғалуының маңызды қауіп факторы болып табылады. Дүние жүзіндегі әртүрлі бағалаулар бойынша ФСГС жиілігі миллионға шаққанда 1,4-тен 21 жағдайға дейін өзгереді. ФСГС бүйрек шумағының (подоциттер) висцеральды эпителий жасушаларының зақымдалуына байланысты дамиды және"подоцитопатиялар"тобына жатады. Бұл зерттеудің мақсатыклиникалық жағдай негізінде нефротикалық синдромның дамуымен ФСГС ауруының ерте оралуын көрсету және қысқа мерзімді перспективада плазмаферез сеанстарының орындылығын бағалау болып табылады. Әдістері:мақалада нефротикалык синдромының дамуымен ФСГС ауруының ерте оралуы болған клиникалық жағдай сипатталған. Бүйрек трансплантациясынан кейін аурудың...
- 14 November 2024
- Published by Semey Medical University in Наука и здравоохранение
- No. 4(26),p. 261-266
Open AccessPRIMARY RECURRENT FOCAL SEGMENTAL GLOMERULOSCLEROSIS AFTER KIDNEY TRANSPLANTATION. CASE STUDY.
Primary recurrent focal segmental glomerulosclerosis (FSGS) after kidney transplantation (KT) is a serious complication and a significant risk factor for graft loss. The incidence of FSGS worldwide varies from 1.4 to 21 cases per million population. FSGS develops due to damage to the visceral epithelial cells of the kidney glomerulus (podocytes) and is classified as a "podocytopathy." Objective. This study aims to demonstrate an early recurrence of FSGS with the development of nephrotic syndrome based on a clinical case and to evaluate the short-term feasibility of plasmapheresis sessions. Methods. The article describes a clinical case of early recurrence of FSGS with the development of nephrotic syndrome. The primary treatment for disease recurrence after kidney transplantation includes plasmapheresis sessions and the administration of rituximab. Results. Analysis of the clinical case revealed that kidney graft thrombosis was a consequence of a drop in blood pressure and a slowdown in blood flow at the anastomosis site during a plasmapheresis session, ultimately leading to graft loss and the patient's return to dialysis therapy. Conclusions. For subsequent planned kidney transplantation, the patient is at extremely high risk of disease recurrence according to the literature, making the procedure not feasible in the short term. Первичный рецидивирующий фокально-сегментарный гломерулосклероз (ФСГС) после трансплантации почки (ТП) является серьезным осложнением и значимым фактором риска потери трансплантированной почки. По разным оценкам в мире заболеваемость ФСГС варьируется от 1,4 до 21 случая на миллион населения. ФСГС развивается вследствие повреждения висцеральных эпителиальных клеток клубочка почек (подоцитов) и относится к группе «подоцитопатий». Целью данного исследования. На примере описанного клинического случая указать на необходимость оценки рисков возврата заболевания ФСГС после трансплантации почки, ввиду быстрого возврата заболевания с развитием нефротического синдрома с потерей функции пересаженного органа. В статье описывается клинический случай проведения трансплантации почки от живого родственного донора, у пациента с хронической болезнью почек 5 стадии в исходе ФСГС, с ранним возвратом заболевания De novo, с развитием нефротического синдрома. Основным лечением в рецидиве заболевания после трансплантации почки является проведение сеансов плазмофереза и введение ритуксимаба. Результаты исследования. В результате анализа клинического случая было выявлено, что тромбоз трансплантата почки явился следствием падения артериального давления и замедления скорости кровотока в зоне анастомоза на фоне проведенного сеанса плазмафереза, что в конечном итоге привело к потере графта и возврата пациента на заместительную почечную терапию. Выводы. Для последующей предполагаемой трансплантации почки по литературным данным пациент имеет крайне высокие риски возврата заболевания, что делает проведение данной процедуры в краткосрочной перспективе не целесообразным. Бүйрек трансплантациясынан кейінгі бастапқы қайталанатын фокальді-сегменттік гломерулосклероз (ФСГС) ауыр асқыну және трансплантацияланған бүйректің жоғалуының маңызды қауіп факторы болып табылады. Дүние жүзіндегі әртүрлі бағалаулар бойынша ФСГС жиілігі миллионға шаққанда 1,4-тен 21 жағдайға дейін өзгереді. ФСГС бүйрек шумағының (подоциттер) висцеральды эпителий жасушаларының зақымдалуына байланысты дамиды және"подоцитопатиялар"тобына жатады. Бұл зерттеудің мақсатыклиникалық жағдай негізінде нефротикалық синдромның дамуымен ФСГС ауруының ерте оралуын көрсету және қысқа мерзімді перспективада плазмаферез сеанстарының орындылығын бағалау болып табылады. Әдістері:мақалада нефротикалык синдромының дамуымен ФСГС ауруының ерте оралуы болған клиникалық жағдай сипатталған. Бүйрек трансплантациясынан кейін аурудың...
- Open Access
- 25 April 2024
- Published by JSC National Scientific Medical Research Center in Journal of Clinical Medicine of Kazakhstan
- Vol. 21 (2) , 11-17
Influence of Genetic Polymorphisms in CYP3A5, CYP3A4, and MDR1 on Tacrolimus Metabolism after kidney transplantation
Kidney transplantation stands as the ultimate recourse for restoring vital organ functions, particularly in cases of end-stage kidney disease where alternative treatments, such as dialysis, prove less effective. With over 102,000 kidney transplants conducted globally in 2022, the demand for organ transplantation is ever-increasing, fueled by a rising incidence of end-stage renal disease attributed to causes like diabetes and hypertension. Despite significant advancements in kidney transplantation, immunosuppressive therapy remains crucial to preventing graft rejection. Tacrolimus (TAC), a calcineurin inhibitor, plays a pivotal role in this regard. Discovered in 1984, TAC inhibits T-lymphocyte activation, preventing acute rejection by disrupting the transcription of crucial genes involved in early T-cell activation. However, the use of TAC is not without challenges. The drug exhibits serious side effects, a narrow therapeutic index, and unpredictable pharmacokinetics. Therapeutic drug monitoring (TDM) becomes imperative in daily practice to maintain TAC blood concentrations within the therapeutic range. This literature review delves into the genetic aspects influencing TAC metabolism, focusing on key polymorphisms in CYP3A5, CYP3A4, and ABCB1 genes. Genetic variations in CYP3A5, a major enzyme in TAC metabolism, impact enzyme activity, necessitating personalized dosing strategies. CYP3A4 polymorphisms, especially CYP3A4*22, demonstrate associations with altered TAC clearance and dose requirements. The ABCB1 gene, encoding P-glycoprotein, another player in TAC pharmacokinetics, also exhibits polymorphisms influencing drug absorption and distribution. The ABCB1 3435C>T variant, in particular, shows potential implications on Tacrolimus bioavailability. Understanding these genetic variations aids in the development of personalized dosing regimens. Studies suggest that tailoring TAC doses based on CYP3A5 genotypes significantly improves the proportion of patients achieving therapeutic concentrations. Additionally, incorporating genetic information, particularly CYP3A4*22, into dosing strategies enhances the precision of TAC therapy, reducing the risk of adverse effects.
- 25 April 2024
- Published by JSC National Scientific Medical Research Center in Journal of Clinical Medicine of Kazakhstan
- Vol. 21 (2) , 11-17
Open AccessInfluence of Genetic Polymorphisms in CYP3A5, CYP3A4, and MDR1 on Tacrolimus Metabolism after kidney transplantation
Kidney transplantation stands as the ultimate recourse for restoring vital organ functions, particularly in cases of end-stage kidney disease where alternative treatments, such as dialysis, prove less effective. With over 102,000 kidney transplants conducted globally in 2022, the demand for organ transplantation is ever-increasing, fueled by a rising incidence of end-stage renal disease attributed to causes like diabetes and hypertension. Despite significant advancements in kidney transplantation, immunosuppressive therapy remains crucial to preventing graft rejection. Tacrolimus (TAC), a calcineurin inhibitor, plays a pivotal role in this regard. Discovered in 1984, TAC inhibits T-lymphocyte activation, preventing acute rejection by disrupting the transcription of crucial genes involved in early T-cell activation. However, the use of TAC is not without challenges. The drug exhibits serious side effects, a narrow therapeutic index, and unpredictable pharmacokinetics. Therapeutic drug monitoring (TDM) becomes imperative in daily practice to maintain TAC blood concentrations within the therapeutic range. This literature review delves into the genetic aspects influencing TAC metabolism, focusing on key polymorphisms in CYP3A5, CYP3A4, and ABCB1 genes. Genetic variations in CYP3A5, a major enzyme in TAC metabolism, impact enzyme activity, necessitating personalized dosing strategies. CYP3A4 polymorphisms, especially CYP3A4*22, demonstrate associations with altered TAC clearance and dose requirements. The ABCB1 gene, encoding P-glycoprotein, another player in TAC pharmacokinetics, also exhibits polymorphisms influencing drug absorption and distribution. The ABCB1 3435C>T variant, in particular, shows potential implications on Tacrolimus bioavailability. Understanding these genetic variations aids in the development of personalized dosing regimens. Studies suggest that tailoring TAC doses based on CYP3A5 genotypes significantly improves the proportion of patients achieving therapeutic concentrations. Additionally, incorporating genetic information, particularly CYP3A4*22, into dosing strategies enhances the precision of TAC therapy, reducing the risk of adverse effects.
- Open Access
- 27 December 2021
- Published by JSC National Scientific Medical Research Center in Journal of Clinical Medicine of Kazakhstan
- Vol. 18 (6) , 32-34
Desensitization in kidney transplantation: Review
Sensitization to human leukocyte antigens (HLA) antigens is the main obstacle to getting the kidney either from a living or deceased donor. HLA sensitization occurs as the result of repeated pregnancy, blood transfusion, or previous transplantation. Overcoming the HLA incompatibility is one of the approaches to decrease the organ shortage. There are 3.5 % highly sensitized patients among 3012 patients on the waiting list for kidney transplantation in Kazakhstan. In this review, we have discussed most common approaches of desensitization for HS kidney recipients. Huge progress has been made in the field of desensitization in transplant medicine worldwide. We suppose, that implementation the desensitization protocols in clinical guidelines will improve patient survival and outcome after kidney transplantation.
- 27 December 2021
- Published by JSC National Scientific Medical Research Center in Journal of Clinical Medicine of Kazakhstan
- Vol. 18 (6) , 32-34
Open AccessDesensitization in kidney transplantation: Review
Sensitization to human leukocyte antigens (HLA) antigens is the main obstacle to getting the kidney either from a living or deceased donor. HLA sensitization occurs as the result of repeated pregnancy, blood transfusion, or previous transplantation. Overcoming the HLA incompatibility is one of the approaches to decrease the organ shortage. There are 3.5 % highly sensitized patients among 3012 patients on the waiting list for kidney transplantation in Kazakhstan. In this review, we have discussed most common approaches of desensitization for HS kidney recipients. Huge progress has been made in the field of desensitization in transplant medicine worldwide. We suppose, that implementation the desensitization protocols in clinical guidelines will improve patient survival and outcome after kidney transplantation.